This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Changes made to Diageo’s board of directors
By Melita KielyDrinks giant Diageo has appointed Emma Walmsley as non-executive director commencing 1 January 2016.
Diageo has appointed Emma Walmsley as non-executive director, effective 1 January 2016Walmsley will be part of the audit, the nomination and the remuneration committees when she joins the board next year.
Her appointment comes as Diageo also announced that Laurence Danon will step down at the firm’s annual general meeting on 23 September.
“I look forward to welcoming Emma to Diageo’s board,” commented Dr Franz Humer, Diageo chairman. “She brings to Diageo a strong blend of commercial and marketing insight.
“She has significant experience in consumer products, and understands the consumer mindset and how to shape consumer trends.
“Her work across mature and fast developing countries will support us as we embed our expanded geographic footprint and maximise our strong platform for growth.
“I would like to thank Laurence Danon for her contribution as a non-executive director over the last nine years.
“Laurence has been a valued member of the board during a period of progress and growth for Diageo.”
At present, Walmsley is chief executive officer of GSK Consumer Healthcare, a global joint venture between GSK and Novartis, and is responsible for overseeing the OTC healthcare company.
Walmsley previously worked as president of GSK Consumer Healthcare and has been a member of the company’s executive team since 2011.